45 Résultats pour : « STILLA TECHNOLOGIES, INC. »

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of KRAS mutations and its positive control. The KRAS (G12C, drop-off G12-G13) Crystal Digital PCR® assay is a 10X assay designed to detect and quantify mutations in codons 12 and 13 plus one mutation of the KRAS gene. KRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Routine Operational Qualification (OQ) procedures of the naica® system and Nio™+ can be performed using the naica® IQ/OQ Kit.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of EGFR mutations and its Positive Control. The EGFR (drop-off Del19) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify EGFR Exon 19 deletion mutations using the Ruby Chip. EGFR encodes for the epidermal growth factor receptor, a protein that plays a crucial role in cell growth, proliferation, and differentiation.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of BRAF/KRAS/NRAS mutations and its positive control. The BRAF/KRAS/NRAS Crystal Digital PCR® assay is a 10X assay designed to detect and quantify mutations in BRAF, KRAS, and NRAS genes using the ruby chip. BRAF, KRAS, and NRAS genes are pivotal in regulating cell signaling pathways implicated in cancer development.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its positive control.The NRAS (drop-off Q61) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations in Q61 of the NRAS gene using the Ruby Chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its positive control. NRAS (Q61K, drop-off Q61) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations in Q61 plus 1 mutation of the NRAS gene. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of ESRI mutations and its positive control. ESR1 (11 mutations) Crystal Digital PCR® assay is a 10X assay designed to detect and quantify 11 mutations in the ESR1 gene using the ruby chip. ESR1 is pivotal in mediating resistance to endocrine therapy in metastatic hormone-positive breast cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of HPV genotypes and its Positive Control. HPV (ALB, HPV16/18/31/33/35/39/45/51/52/56/58) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 11 high risk HPV genotypes for cervical cancer plus a reference gene for human DNA quantification using the Ruby Chip.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its positive control. NRAS (G12D, drop-off G12-G13) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations in G12-G13 plus 1 mutation of the NRAS gene using the Ruby Chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its Positive Control. NRAS (Q61, Q61R, Q61K) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 2 mutations in the NRAS gene using the Ruby Chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of KRAS mutations and its positive control. The KRAS (G12A, G12C, G12D, G12V, drop-off G12-G13) Crystal Digital PCR® assay is a 10X assay designed to detect and quantify mutations in codons 12 and 13 plus 4 mutations in the KRAS gene using the ruby chip. KRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of RAD51C Methylation and its positive control. The RAD51C methylation Crystal Digital PCR® assay is a 10X assay designed to detect and quantify methylation of the RAD51C promoter using the ruby chip. RAD51C gene is involved in DNA repair, particularly in the homologous recombination pathway for genome stability.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of TP53 mutations and its Positive Control. TP53 (drop-off V272-A276/G280-R283) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify mutations between V272-A276 or G280-R283 of the TP53 gene using the Ruby Chip. TP53 is pivotal in regulating cell divisison, thus an important tumor suppressor gene.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific Crystal Flex Probes and primers for the detection of NRAS mutations and its Positive Control. NRAS (Q61, Q61K) Crystal Digital PCR® Assay is a 10X assay designed to detect and quantify 1 mutation in the NRAS gene using the Ruby Chip. NRAS is pivotal in regulating cell signaling pathways implicated in cancer development, notably melanoma and colorectal cancer.

Supplier: STILLA TECHNOLOGIES, INC.

Assay-specific crystal flex probes and primers for the detection of BRCA1/RAD51C/GSTP1 methylation and its positive control. The BRCA1/RAD51C/GSTP1 methylation Crystal Digital PCR® assay is a 10X assay designed to detect and quantify methylation of the BRCA1, RAD51C, and GSTP1 promoter using the ruby chip. Methylation of the BRCA1, RAD51C, and GSTP1 affects DNA repair mechanisms crucial for genome stability and dysregulation of detoxification pathways, both contributing to tumor initiation, progression, and drug resistance.